- Home
- ADI vs GILD Comparison
ADI vs GILD Comparison
Compare ADI & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADI | GILD |
|---|---|---|
| Founded | 1965 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.9B | 168.6B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ADI | GILD |
|---|---|---|
| Price | $400.83 | $131.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 18 |
| Target Price | ★ $385.45 | $148.39 |
| AVG Volume (30 Days) | 2.8M | ★ 4.3M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | 1.13% | ★ 2.55% |
| EPS Growth | 39.02 | ★ 1684.21 |
| EPS | 1.69 | ★ 6.78 |
| Revenue | $6,200,942,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $28.41 | $4.68 |
| Revenue Next Year | $10.25 | $6.04 |
| P/E Ratio | $230.73 | ★ $18.97 |
| Revenue Growth | ★ 21.41 | 9.98 |
| 52 Week Low | $194.26 | $95.30 |
| 52 Week High | $408.37 | $157.29 |
Technical Indicators
Market Signals| Indicator | ADI | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 70.41 | 38.49 |
| Support Level | $223.69 | $116.55 |
| Resistance Level | $408.37 | $142.33 |
| Average True Range (ATR) | 9.90 | 2.91 |
| MACD | 2.53 | -0.62 |
| Stochastic Oscillator | 89.07 | 25.22 |
Price Performance
Historical ComparisonAbout ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).